
FDA delays review of Exelixis' zanzalintinib by 3 months, no new safety issues found
The FDA extended its review of Exelixis' cancer drug zanzalintinib by three months without revealing any new clinical failures or safety concerns. This delay reduces the drug's present value by about 2.35%, which is less than the initial market loss....





